Frank Buttgereit

Q: What Schools Are Affiliated With Frank Buttgereit

Frank Buttgereit is affiliated with the following schools: Humboldt University of Berlin, University of California, Berkeley, Stanford University, University of Groningen

Frank Buttgereit's AcademicInfluence.com Rankings

Frank Buttgereit

Engineering

#4238

World Rank

#5423

Historical Rank

Electrical Engineering

#1059

World Rank

#1140

Historical Rank

engineering Degrees

Frank Buttgereit

Computer Science

#5426

World Rank

#5734

Historical Rank

Data Science

#87

World Rank

#89

Historical Rank

Computational Linguistics

#754

World Rank

#767

Historical Rank

Machine Learning

#1442

World Rank

#1464

Historical Rank

computer-science Degrees

Download Badge

Engineering
Computer Science

Frank Buttgereit's Degrees

PhD Computer Science Stanford University
Masters Electrical Engineering University of California, Berkeley
Bachelors Mathematics University of California, Berkeley

Similar Degrees You Can Earn

Why Is Frank Buttgereit Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Frank Buttgereit's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010) (2474)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update (2013) (1711)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update (2020) (1453)
A hierarchy of ATP-consuming processes in mammalian cells. (1995) (718)
Quantitating protein synthesis, degradation, and endogenous antigen processing. (2003) (523)
Genomic and nongenomic effects of glucocorticoids (2008) (509)
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data (2005) (484)
2018 Update of the EULAR recommendations for the management of large vessel vasculitis (2019) (459)
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology (2002) (408)
Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists (2007) (392)
Dose-related patterns of glucocorticoid-induced side effects (2008) (383)
Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial (2008) (328)
Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. (2004) (325)
The early fracture hematoma and its potential role in fracture healing. (2010) (323)
Energy regulation and neuroendocrine–immune control in chronic inflammatory diseases (2010) (317)
Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. (2016) (314)
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases (2007) (309)
Rapid glucocorticoid effects on immune cells (2002) (294)
Bioenergetics of immune functions: fundamental and therapeutic aspects. (2000) (277)
Association among rheumatoid arthritis, oral hygiene, and periodontitis. (2008) (258)
The association between rheumatoid arthritis and periodontal disease (2010) (257)
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force (2016) (235)
Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up‐regulated after in vitro stimulation and in patients with rheumatoid arthritis (2004) (229)
A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. (1998) (226)
The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease (2016) (222)
EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases (2013) (222)
Inflammatory phase of bone healing initiates the regenerative healing cascade (2012) (211)
Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands (2008) (195)
Molecular mechanisms of glucocorticoid-induced osteoporosis. (2001) (195)
2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative (2015) (190)
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study (2012) (189)
Non-genomic glucocorticoid effects to provide the basis for new drug developments (2006) (187)
Optimised glucocorticoid therapy: the sharpening of an old spear (2005) (184)
Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. (2005) (178)
Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice (2010) (168)
Metabolic regulation of inflammation (2017) (166)
Hypoxia Promotes Osteogenesis but Suppresses Adipogenesis of Human Mesenchymal Stromal Cells in a Hypoxia-Inducible Factor-1 Dependent Manner (2012) (165)
Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. (2012) (165)
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2) (2012) (161)
Association Among Rheumatoid Arthritis, Oral Hygiene, and Periodontitis (2008) (159)
Glucocorticoids cause rapid dissociation of a T‐cell‐receptor‐associated protein complex containing LCK and FYN (2006) (157)
Human Early Fracture Hematoma Is Characterized by Inflammation and Hypoxia (2011) (156)
Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do! (2005) (150)
Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. (1999) (149)
Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities (2017) (147)
Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab (2011) (146)
Signaling takes a breath--new quantitative perspectives on bioenergetics and signal transduction. (2001) (145)
Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders (2001) (132)
2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative (2015) (131)
Glucocorticoids—All-Rounders Tackling the Versatile Players of the Immune System (2019) (129)
Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis (2016) (125)
Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis (2010) (122)
Initial immune reaction and angiogenesis in bone healing (2014) (120)
Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases (2009) (120)
The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis (2005) (119)
Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. (2001) (118)
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. (2020) (116)
Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis (2010) (108)
[EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases]. (2009) (102)
CD73 and CD29 concurrently mediate the mechanically induced decrease of migratory capacity of mesenchymal stromal cells. (2011) (100)
Exogenous and endogenous glucocorticoids in rheumatic diseases. (2011) (91)
Optimized glucocorticoid therapy: Teaching old drugs new tricks (2013) (91)
Clocking in: chronobiology in rheumatoid arthritis (2015) (90)
Osteoarthritis synovial fluid activates pro-inflammatory cytokines in primary human chondrocytes (2012) (84)
The influence of obesity on perioperative morbidity and mortality in revision total hip arthroplasty (2000) (82)
European Guideline on IgG4-related digestive disease – UEG and SGF evidence-based recommendations (2020) (81)
Cellular composition of the initial fracture hematoma compared to a muscle hematoma: A study in sheep (2009) (81)
Bioenergetics of Human Peripheral Blood Mononuclear Cell Metabolism in Quiescent, Activated, and Glucocorticoid-Treated States (2000) (77)
Hypothalamus-Pituitary-Adrenal Axis Function in Patients with Rheumatoid Arthritis Treated with Nighttime-Release Prednisone (2010) (77)
[Selective COX-2 inhibition improves endothelial function in coronary artery disease]. (2003) (75)
IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease (2010) (75)
Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside (2008) (74)
Origin and functional activity of the membrane-bound glucocorticoid receptor. (2011) (70)
Alterations of the hypothalamic-pituitary-adrenal axis in systemic immune diseases - a role for misguided energy regulation. (2011) (70)
Quantification of ATP-producing and consuming processes of Ehrlich ascites tumour cells. (1986) (68)
Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells. (2003) (68)
Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis. (2008) (67)
Localized pigmented villonodular synovitis of the knee joint: neoplasm or reactive granuloma? A review of 18 cases. (2000) (66)
Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. (2005) (65)
Glucocorticoids in rheumatoid arthritis: current status and future studies (2020) (63)
Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism. (2011) (62)
Hypoxia: how does the monocyte‐macrophage system respond to changes in oxygen availability? (2014) (61)
New Glucocorticoids on the Horizon: Repress, Don't Activate! (2005) (61)
Immunological characterization of the early human fracture hematoma (2016) (60)
Circadian rhythms in rheumatology - a glucocorticoid perspective (2014) (58)
Methylprednisolone inhibits uptake of Ca2+ and Na+ ions into concanavalin A-stimulated thymocytes. (1997) (55)
Benefit of pregnancy in inflammatory arthritis (2005) (54)
Macrophage Migration Inhibitory Factor Counterregulates Dexamethasone-Mediated Suppression of Hypoxia-Inducible Factor-1α Function and Differentially Influences Human CD4+ T Cell Proliferation under Hypoxia (2011) (54)
Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rheumatic diseases. (2000) (53)
Non-surgical management of knee osteoarthritis: where are we now and where do we need to go? (2015) (52)
Membrane glucocorticoid receptors are down regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent expression pathway (2006) (52)
Beta2-adrenergic receptors mediate the differential effects of catecholamines on cytokine production of PBMC. (2005) (51)
Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). (2010) (51)
Prevalence and clinical significance of anticardiolipin and anti‐β2‐glycoprotein‐I antibodies in patients with non‐Hodgkin's lymphoma (2002) (51)
Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum-induced arthritis in vivo. (2009) (50)
Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries (2020) (50)
The effects of methylprednisolone on oxidative phosphorylation in Concanavalin-A-stimulated thymocytes. Top-down elasticity analysis and control analysis. (1994) (50)
Impact of impaired morning function on the lives and well-being of patients with rheumatoid arthritis (2011) (50)
Periodontal disease in patients with ankylosing spondylitis (2009) (49)
Human CD4+ T cells maintain specific functions even under conditions of extremely restricted ATP production (2008) (49)
Pharmacology of glucocorticoids in rheumatoid arthritis. (2010) (48)
Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis (2019) (48)
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. (2020) (48)
Views on glucocorticoid therapy in rheumatology: the age of convergence (2020) (48)
Effects of Porphyromonas gingivalis on cell cycle progression and apoptosis of primary human chondrocytes (2008) (47)
Adaptation of Human CD4+ T Cells to Pathophysiological Hypoxia: A Transcriptome Analysis (2009) (46)
Higher expression of glucocorticoid receptor in peripheral mononuclear cells in inflammatory bowel disease (2000) (45)
Influencing Factors on Perioperative Morbidity in Knee Arthroplasty (2000) (44)
Effects of 60-day bed rest with and without exercise on cellular and humoral immunological parameters (2014) (43)
Effects of hypoxia and/or lack of glucose on cellular energy metabolism and cytokine production in stimulated human CD4+ T lymphocytes. (2010) (43)
Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis (2019) (43)
Human immune cells' behavior and survival under bioenergetically restricted conditions in an in vitro fracture hematoma model (2013) (43)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update (2022) (42)
The challenge of continuous exogenous glucocorticoid administration in mice (2009) (42)
“Official View” on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements (2017) (41)
Mechanisms and clinical relevance of nongenomic glucocorticoid actions (2000) (41)
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial (2020) (40)
Effects of the mitogen concanavalin A on pathways of thymocyte energy metabolism. (1999) (40)
Tumoral calcinosis revisited: pathophysiology and treatment (2003) (39)
Effect of Glucocorticoid Therapy on Glucocorticoid Receptors in Children with Autoimmune Diseases (2001) (39)
Pharmacodynamics of glucocorticoids. (2011) (39)
Bioenergetics of immune cells to assess rheumatic disease activity and efficacy of glucocorticoid treatment (2003) (38)
Energy metabolism and rheumatic diseases: from cell to organism (2012) (38)
Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica (2020) (38)
Recruitment and Retention of Older People in Clinical Research: A Systematic Literature Review (2020) (37)
Unraveling the functions of the membrane‐bound glucocorticoid receptors: first clues on origin and functional activity (2014) (37)
Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone (2014) (37)
Inflammatory synovial fluid microenvironment drives primary human chondrocytes to actively take part in inflammatory joint diseases (2012) (37)
Glucocorticoids in the treatment of rheumatoid arthritis. (2015) (37)
Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database (2018) (36)
Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice. (2000) (36)
Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies. (2016) (35)
Developments in glucocorticoid therapy. (2005) (35)
2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis (2018) (35)
Human monocytes and macrophages differ in their mechanisms of adaptation to hypoxia (2012) (35)
Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis. (2018) (35)
A Pronounced Inflammatory Activity Characterizes the Early Fracture Healing Phase in Immunologically Restricted Patients (2017) (35)
Direct Crosstalk Between Cancer and Osteoblast Lineage Cells Fuels Metastatic Growth in Bone via Auto‐Amplification of IL‐6 and RANKL Signaling Pathways (2014) (35)
Norepinephrine Inhibits Energy Metabolism of Human Peripheral Blood Mononuclear Cells via Adrenergic Receptors (2001) (34)
Low‐dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy (2010) (34)
Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis (2017) (34)
Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. (2016) (34)
Induced Apoptosis of Chondrocytes by Porphyromonas gingivalis as a Possible Pathway for Cartilage Loss in Rheumatoid Arthritis (2010) (33)
Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial (2018) (33)
Prevention of glucocorticoid morbidity in giant cell arteritis (2018) (33)
Immunologically restricted patients exhibit a pronounced inflammation and inadequate response to hypoxia in fracture hematomas (2011) (32)
Treatment of chronic plantar fasciitis with botulinum toxin A: an open case series with a 1 year follow up (2005) (32)
Effects of methylprednisolone on the energy metabolism of quiescent and conA-stimulated thymocytes of the rat (1993) (31)
The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica (2017) (30)
ConA induced changes in energy metabolism of rat thymocytes (1992) (30)
Effects of PVA coated nanoparticles on human immune cells (2015) (30)
More Night Than Day — Circadian Rhythms in Polymyalgia Rheumatica and Ankylosing Spondylitis (2010) (29)
An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis (2019) (28)
The novel strategy of glucocorticoid drug development via targeting nongenomic mechanisms (2015) (28)
Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis? (2011) (28)
Fatal atypical T‐cell proliferation associated with Epstein–Barr virus infection (2001) (28)
[Prophylaxis and treatment of osteoporosis in patients with rheumatoid arthritis (ORA study)]. (2011) (27)
Spatial Distribution of Macrophages During Callus Formation and Maturation Reveals Close Crosstalk Between Macrophages and Newly Forming Vessels (2019) (27)
Unraveling the role of hypoxia-inducible factor (HIF)-1α and HIF-2α in the adaption process of human microvascular endothelial cells (HMEC-1) to hypoxia: Redundant HIF-dependent regulation of macrophage migration inhibitory factor. (2018) (26)
Novel glucocorticoids: where are we now and where do we want to go? (2015) (26)
Methotrexate treatment in large vessel vasculitis and polymyalgia rheumatica. (2010) (25)
Circadian rhythms of cellular immunity in rheumatoid arthritis: a hypothesis-generating study. (2015) (25)
CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells (2018) (25)
Cytokine Expression in Human Osteoblasts After Antiseptic Treatment: A Comparative Study Between Polyhexanide and Chlorhexidine (2015) (25)
Therapeutically targeting lymphocyte energy metabolism by high-dose glucocorticoids. (2000) (24)
Impact of morning stiffness on working behaviour and performance in people with rheumatoid arthritis (2014) (24)
Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial (2014) (24)
Preoperative irradiation for the prevention of heterotopic ossification induces local inflammation in humans. (2013) (23)
Membrane glucocorticoid receptor expression on peripheral blood mononuclear cells in patients with ankylosing spondylitis. (2006) (22)
Prednisone chronotherapy. (2011) (22)
Collagen I-based scaffolds negatively impact fracture healing in a mouse-osteotomy-model although used routinely in research and clinical application. (2019) (22)
Pathophysiological hypoxia affects the redox state and IL‐2 signalling of human CD4+ T cells and concomitantly impairs survival and proliferation (2013) (22)
Anti-tumour necrosis factor α therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment (2009) (21)
Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study (2017) (21)
[S3 guidelines on treatment of polymyalgia rheumatica : Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and othe (2018) (21)
Increased Periodontal Attachment Loss in Patients With Systemic Sclerosis. (2016) (21)
Effects of methylprednisolone and 21-aminosteroids on mitogen-induced interleukin-6 and tumor necrosis factor-alpha production in human peripheral blood mononuclear cells. (1995) (21)
Inflammation, glucocorticoids and risk of cardiovascular disease (2009) (21)
Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing (2020) (20)
Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis. (2012) (20)
The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis (2014) (20)
Modification of the surface of superparamagnetic iron oxide nanoparticles to enable their safe application in humans (2016) (20)
Glucocorticoids in rheumatoid arthritis: the picture is shaping up (2017) (20)
ConA induced changes in energy metabolism of rat thymocytes (1992) (20)
Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study (2019) (20)
Rheumatology Workforce Planning in Western Countries: A Systematic Literature Review (2016) (20)
A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis. (2013) (20)
Arterial thrombosis associated with anticardiolipin and anti‐β2‐glycoprotein‐Iantibodies in patients with non‐Hodgkin's lymphoma: a report of two cases (2000) (20)
Administration of Tramadol or Buprenorphine via the drinking water for post-operative analgesia in a mouse-osteotomy model (2019) (20)
The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine. (2010) (20)
Cellular Energy Metabolism in T-Lymphocytes (2015) (19)
Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases. (2003) (19)
Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis. (2016) (19)
Oxygen consumption and mitochondrial membrane potential indicate developmental adaptation in energy metabolism of rat cortical neurons (2005) (19)
A fresh look at glucocorticoids how to use an old ally more effectively. (2012) (19)
Will we ever have better glucocorticoids? (2017) (19)
Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey (2017) (19)
Challenges, collaboration, and innovation in rheumatology education during the COVID-19 pandemic: leveraging new ways to teach (2020) (19)
Hypoxia and mesenchymal stromal cells as key drivers of initial fracture healing in an equine in vitro fracture hematoma model (2019) (18)
[Insufficiency fractures in rheumatology. Case report and overview]. (2006) (17)
A HIERARCHY OF ATP-CONSUMING PROCESSES (1996) (17)
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial (2022) (17)
EULAR ‘points to consider’ for the conduction of workforce requirement studies in rheumatology (2018) (17)
How should impaired morning function in rheumatoid arthritis be treated? (2011) (17)
Effects of tacrolimus, cyclosporin A and sirolimus on MG63 cells (2006) (16)
Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis (2015) (16)
Quantification of ATP-producing and consuming processes in quiescent pig spleen lymphocytes. (1991) (16)
Analyses of similarities and differences in glucocorticoid therapy between rheumatoid arthritis and ankylosing spondylitis - a systematic comparison. (2009) (16)
Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone (2015) (16)
Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review (2017) (16)
The 70th anniversary of glucocorticoids in rheumatic diseases: the second youth of an old friend (2018) (16)
Regulation of glucocorticoids by the central nervous system. (2011) (15)
Polyarteritis nodosa and testicular pain: ultrasonography reveals vasculitis of the testicular artery. (2007) (15)
Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells. (2010) (15)
Metabolism of T Lymphocytes in Health and Disease. (2019) (15)
Arthritis and endogenous glucocorticoids: the emerging role of the 11β-HSD enzymes (2007) (14)
What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis? (2015) (14)
Transgenic Disruption of Glucocorticoid Signaling in Osteoblasts Attenuates Joint Inflammation in Collagen Antibody-Induced Arthritis. (2016) (14)
Nanocoating with plant-derived pectins activates osteoblast response in vitro (2016) (13)
Differences in biomarkers of cartilage matrix turnover and their changes over 2 years in adolescent and adult volleyball athletes (2017) (13)
Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider (2018) (13)
A case of Erdheim–Chester disease initially mistaken for Ormond's disease (2008) (13)
Sustained Increase of 25-Hydroxyvitamin D Levels in Healthy Young Women during Wintertime after Three Suberythemal UV Irradiations—The MUVY Pilot Study (2016) (13)
Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people. (2019) (13)
Disentangling the effects of tocilizumab on neutrophil survival and function (2016) (13)
Membrane glucocorticoid receptors (mGCR) on monocytes are up-regulated after vaccination. (2006) (13)
Preferred use of polyhexanide in orthopedic surgery. (2011) (12)
Prevalence and clinical significance of anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin's lymphoma. (2002) (12)
Delayed-release prednisone – a new approach to an old therapy (2013) (12)
The Impact of Porphyromonas gingivalis Lipids on Apoptosis of Primary Human Chondrocytes (2012) (11)
Granulomatous synovialitis with erosions in the shoulder joint: a rare case of polyarthritis caused by Mycobacterium kansasii (2005) (11)
Association between changes in molecular biomarkers of cartilage matrix turnover and changes in knee articular cartilage: a longitudinal pilot study (2019) (11)
Inflammation Is an Important Covariate for the Crosstalk of Sleep and the HPA Axis in Rheumatoid Arthritis (2017) (11)
Can adverse effects of glucocorticoid therapy be prevented and treated? (2016) (11)
Potencies of topical glucocorticoids to mediate genomic and nongenomic effects on human peripheral blood mononuclear cells. (2006) (11)
Effects of dexamethasone and celecoxib on calcium homeostasis and expression of cyclooxygenase-2 mRNA in MG-63 human osteosarcoma cells. (2006) (11)
Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy (2006) (10)
[S2k guidelines: management of large-vessel vasculitis]. (2020) (10)
CD 73 AND CD 29 CONCURRENTLY MEDIATE THE MECHANICALLY INDUCED DECREASE OF MIGRATORY CAPACITY OF MESENCHYMAL STROMAL CELLS (10)
Quantification of periarticular demineralization and synovialitis of the hand in rheumatoid arthritis patients (2012) (10)
Anti-tumour necrosis factor antibody treatment does not change serum levels of cortisol binding globulin in patients with rheumatoid arthritis but it increases androstenedione relative to cortisol (2005) (10)
Current issues of basic and clinical glucocorticoid research. (2003) (10)
Low-dose glucocorticoids in rheumatic diseases: introduction. (2011) (10)
Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries (2015) (10)
Effects of PVA-coated nanoparticles on human T helper cell activity. (2016) (10)
Gene Expression of Catalytic Proteasome Subunits and Resistance Toward Proteasome Inhibition of B Lymphocytes from Patients with Primary Sjögren Syndrome (2013) (10)
Acute murine antigen-induced arthritis is not affected by disruption of osteoblastic glucocorticoid signalling (2014) (9)
Barriers and potential solutions in the recruitment and retention of older patients in clinical trials-lessons learned from six large multicentre randomized controlled trials. (2021) (9)
Fracture Healing Research—Shift towards In Vitro Modeling? (2021) (9)
Effects of celecoxib on the expression of osteoprotegerin, energy metabolism and cell viability in cultured human osteoblastic cells. (2009) (9)
Polymyalgia Rheumatica and Giant Cell Arteritis. (2020) (9)
Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study—a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial (2021) (9)
Treat to Target: A Valid Concept for Management of Polymyalgia Rheumatica and Giant Cell Arteritis? (2019) (9)
A novel approach to improve detection of glucocorticoid doping in sport with new guidance for physicians prescribing for athletes (2021) (9)
In silico methods - Computational alternatives to animal testing. (2018) (9)
Macroscale mesenchymal condensation to study cytokine-driven cellular and matrix-related changes during cartilage degradation (2020) (8)
Coincidence of asymptomatic avascular necrosis and fracture of the femoral neck: a rare combination of glucocorticoid induced side effects (2002) (8)
[Pathogenesis of parodontitis in rheumatic diseases]. (2010) (8)
OP0030 RANDOMIZED CONTROLLED 24-WEEK TRIAL EVALUATING THE SAFETY AND EFFICACY OF BLINDED TAPERING VERSUS CONTINUATION OF LONG-TERM PREDNISONE (5 MG/D) IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED LOW DISEASE ACTIVITY OR REMISSION ON TOCILIZUMAB (2019) (8)
Patients' and rheumatologists' perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis-an international survey within the GLORIA study. (2021) (8)
Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis. (2015) (8)
Effects of Norepinephrine on Oxygen Consumption of Quiescent and Activated Human Peripheral Blood Mononuclear Cells (2002) (8)
High-Sensitivity Immunofluorescence Staining: A Comparison of the Liposome Procedure and the FASER Technique on mGR Detection (2013) (7)
Relationship between placenta growth factor 1 and vascularization, dehydroepiandrosterone sulfate to dehydroepiandrosterone conversion, or aromatase expression in patients with rheumatoid arthritis and patients with osteoarthritis. (2012) (7)
54 – Systemic glucocorticoids in rheumatology (2015) (7)
[Influence of adjuvant pain medication on quality of life in the treatment of postmenopausal osteoporosis]. (2008) (7)
Modulation of intracellular calcium signaling and mitochondrial function in cultured osteoblastic cells by dexamethasone and celecoxib during mechanical stimulation. (2004) (7)
[High dosage steroid pulse therapy. Is there an indication in dermatology?]. (2000) (7)
The in vitro human fracture hematoma model - a tool for preclinical drug testing. (2020) (7)
Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. (2019) (7)
Which dose regimen for glucocorticoid pulse therapy in patients with severe refractory RA? (2005) (7)
Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis. (2015) (7)
[Diagnosis and treatment of osteoporosis and rheumatoid arthritis in accordance with German guidelines. Results of a survey of patients, primary care physicians and rheumatologists]. (2011) (6)
Intravenous injection of India ink with suicidal intent (1998) (6)
SAT0221 Efficacy and Safety of PF-04171327, a Novel Dissociated Agonist of the Glucocorticoid Receptor (DAGR): Results of a Phase 2, Randomized, Double-Blind Study (2015) (6)
Polymyalgia Rheumatica and Giant Cell Arteritis. (2020) (6)
[Long-term glucocorticoid therapy : Is there a safe dosage?]. (2016) (6)
[Reduction of arthrosis associated knee pain through a single intra-articular injection of synthetic hyaluronic acid]. (2006) (6)
Limited Use of Antiseptics in Septic Surgery (2012) (6)
[Pregnancy-induced algodystrophy]. (1998) (6)
OP0186 HYDROXYCHLOROQUINE IN PATIENTS WITH INFLAMMATORY AND EROSIVE OSTEOARTHRITIS OF THE HANDS: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTRE, INVESTIGATOR-INITIATED TRIAL (OA TREAT) (2020) (6)
Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease (2022) (6)
[Mechanisms of action of high-dosage glucocorticoid therapy]. (1996) (6)
Association Between the Use of Oral Contraceptives and Patient‐Reported Outcomes in an Early Arthritis Cohort (2016) (6)
Plant-derived pectin nanocoatings to prevent inflammatory cellular response of osteoblasts following Porphyromonas gingivalis infection (2017) (6)
[Current insights into the development of new glucocorticoid receptor ligands]. (2005) (6)
Functional Scaffold‐Free Bone Equivalents Induce Osteogenic and Angiogenic Processes in a Human In Vitro Fracture Hematoma Model (2020) (5)
NADPH oxidase 4 represents a potential target for the treatment of osteoporosis (2014) (5)
Role of 11β-HSD type 1 in abnormal HPA axis activity during immune-mediated arthritis (2018) (5)
Association between sarcopenia, physical performance and falls in patients with rheumatoid arthritis: a 1-year prospective study (2021) (5)
Glucocorticoids: surprising new findings on their mechanisms of actions (2020) (5)
Short-Term Effects of the 21-Aminosteroid Lazaroid Tirilazad Mesylate (PNU-74006F) and the Pyrrolopyrimidine Lazaroid PNU-101033E on Energy Metabolism of Human Peripheral Blood Mononuclear Cells (2001) (5)
Clinical image: Isolated arteritis of the superior mesenteric artery with positive perinuclear antineutrophil cytoplasmic antibody. (1998) (5)
MIF does only marginally enhance the pro-regenerative capacities of DFO in a mouse-osteotomy-model of compromised bone healing conditions. (2021) (5)
Increased Periodontal Attachment Loss in Systemic Sclerosis Patients (2016) (5)
Quantifying cutaneous adverse effects of systemic glucocorticoids in patients with rheumatoid arthritis: a cross-sectional cohort study. (2017) (5)
[Mechanism of action and effects of glucocorticoids]. (2001) (5)
A Human Osteochondral Tissue Model Mimicking Cytokine-Induced Key Features of Arthritis In Vitro (2020) (5)
[Disease-modifying effects of glucocorticoids in rheumatoid arthritis]. (2007) (4)
Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition (2022) (4)
OP0145 Induction therapy with adalimumab plus methotrexate versus methotrexate monotherapy in recent onset rheumatoid arthritis (RA) – an investigator initiated randomized controlled trial (2013) (4)
[New developments in glucocorticoid therapy: selective glucocorticoid receptor agonists, nitrosteroids and liposomal glucocorticoids]. (2006) (4)
Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis (2020) (4)
Value of anticardiolipin antibodies for monitoring disease activity in systemic lupus erythematosus and other rheumatic diseases (1997) (4)
Systematic review on the reporting accuracy of experimental details in publications using mouse femoral fracture models. (2021) (4)
[Bone densitometry in inflammatory rheumatic diseases : Characteristics of the measurement site and disease-specific factors]. (2009) (4)
Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis (2022) (4)
How to mechanistically explain the CONDOR study data. (2015) (4)
OP0115 EFFICACY AND SAFETY OF ABBV-3373, A NOVEL ANTI-TNF GLUCOCORTICOID RECEPTOR MODULATOR ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY: A PHASE 2A PROOF OF CONCEPT STUDY (2021) (4)
LB0006 SARILUMAB IN PATIENTS WITH RELAPSING POLYMYALGIA RHEUMATICA: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL (SAPHYR) (2022) (4)
Inflammatory phase of bone healing initiates the regenerative healing cascade (2011) (3)
Can we shift the benefit–risk ratio of glucocorticoids? (2020) (3)
Production of IL-6 and Phagocytosis Are the Most Resilient Immune Functions in Metabolically Compromised Human Monocytes (2021) (3)
Corrigendum to ‘Rapid glucocorticoid effects on immune cells’ [Steroids 67 (2002) 529–534] (2003) (3)
[Neuroendocrine-immunologic mechanisms in rheumatic diseases--a congress report]. (2002) (3)
The influence of Methylprednisolone on the energy metabolism of Ehrlich ascites tumour cells (1994) (3)
FRI0507 THE HUMAN-BASED IN VITRO 3D ARTHRITIC JOINT MODEL (2019) (3)
SAT0535 Eular 2018 core set of data to be collected in giant cell arteritis registries and databases viewpoints from a eular task force (2018) (3)
Development of cervical interspinous bursitis after prolonged sports trauma: a case report. (2006) (3)
Using subdomain-specific item sets affected PROMIS Physical Function scores differently in cardiology and rheumatology patients. (2020) (3)
Surface AMP deaminase 2 as a novel regulator modifying extracellular adenine nucleotide metabolism (2021) (3)
How to taper glucocorticoids in inflammatory rheumatic diseases? A narrative review of novel evidence in rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis. (2021) (3)
Rheumatoid arthritis: Glucocorticoid therapy and body composition (2016) (3)
SAT0333 Prevalence of sarcopenia in patients with systemic sclerosis according to the revised criteria of the european working group on sarcopenia in older people (2017) (2)
[Oral glucocorticoids : Therapeutic use and treatment monitoring in inflammatory rheumatic diseases]. (2019) (2)
Simulating osteoarthritis in vitro with human scaffold-free 3D cartilage transplants (2018) (2)
Glucocorticoid-trials in rheumatoid arthritis mostly study representative real-world patients: A systematic review and meta-analysis. (2020) (2)
[Acute mesenteric ischemia in a patient with relapsing polychondritis]. (2006) (2)
Imaging: Whole-body MRI undresses polymyalgia rheumatica (2016) (2)
FRI0002 Development of an in vitro multi-component 3d joint model to simulate the pathogenesis of arthritis (2017) (2)
AB0915 Bone mineral density and fracture frequencies in patients with psoriasis or psoriasis arthritis (2018) (2)
[Adult onset Still's disease with small vessel vasculitis]. (2015) (2)
[Pharmacotherapy of rheumatic diseases in the aged]. (2003) (2)
The Experiences of Functioning and Health of Patients With Primary Sjögren's Syndrome: A Multicenter Qualitative European Study (2021) (2)
Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort (2022) (2)
[Persistent facial swelling of unclear etiology. The differential diagnostic considerations]. (1997) (2)
Case Number 26: Systemic idiopathic fibrosis associated with aortitis (2003) (2)
Patient and rheumatologist perspectives on glucocorticoids an exercise to improve the implementation of the EULAR recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases (2010) (2)
[Intravenous immunoglobulins in chronic idiopathic myositis]. (2005) (2)
Metabolic reprogramming of synovial fibroblasts in osteoarthritis by inhibition of pathologically overexpressed pyruvate dehydrogenase kinases. (2022) (2)
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence (2022) (2)
THU0069 MIMICKING ARTHRITIS IN VITRO TO TEST DIFFERENT TREATMENT APPROACHES (2020) (2)
THU0286 MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS (2019) (2)
AB1310 PROSPECTIVE USE OF THE GLUCOCORTICOID TOXICITY INDEX (GTI) IN A COHORT OF VASCULITIS PATIENTS (2019) (2)
Looking ahead: giant-cell arteritis in 10 years time (2022) (2)
Persistent pulmonary lesion in a patient with rheumatoid arthritis. (1994) (2)
[The therapeutic potential of lazaroids (21-aminosteroids). A recent survey]. (2008) (2)
[Controlling glucocorticoid treatment in critically ill patients with rheumatism exemplified by systemic lupus erythematosus]. (2019) (2)
[Corticoid research: in non-genomic effects there are still some questions]. (1999) (2)
Influence of PVA coated nanoparticles on survival and functionality of human immune cells (1)
BSR guideline on diagnosis and treatment of giant cell arteritis (2020) (1)
In vitro and in silico modeling of cellular and matrix-related changes during the early phase of osteoarthritis (2019) (1)
AB0029 THE METABOLIC HIERARCHY OF IMMUNE PROCESSES IN HUMAN MONOCYTES (2021) (1)
Glucocorticoid-induced Inhibition of T Cell Receptor Signaling Mediated Through Lck and Fyn: A New Mechanism for an Old Drug (2006) (1)
[Therapy of rheumatic diseases with methylprednisolone--mechanism of action and clinical applications]. (1994) (1)
[Oral glucocorticoids : Therapeutic use and treatment monitoring in inflammatory rheumatic diseases]. (2020) (1)
OP0181 Patient perspectives of people with primary sjÖgren’s syndrome: a multicentre qualitative european study (2018) (1)
Developing Guideline for Polymyalgia Rheumatica: Prioritisation of Outcome Measures - Perspective of Patients, General Practitioners and Rheumatologists (2013) (1)
THU0128 GLUCOCORTICOID TAPERING IN MONTHLY 1-MG DECREMENTS DOES NOT RESULT IN CLINICALLY MANIFEST ADRENAL INSUFFICIENCY IN PATIENTS WITH RHEUMATOID ARTHRITIS: LEARNINGS FROM THE PHASE 3/4 SEMIRA STUDY (2019) (1)
An in vitro human-based fracture gap model – Mimicking the crosstalk between bone and immune cells (2020) (1)
[Prescription of glucocorticoids by rheumatologists in patients with rheumatoid arthritis in Germany]. (2005) (1)
FRI0284 RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS (2019) (1)
Tofacitinib promotes fundamental processes of bone healing (2019) (1)
Reply: Low-dose glucocorticoids in rheumatoid arthritis: blurring the line between therapeutic dose and substitution therapy? (2017) (1)
Reply to: What could a new disease activity score for polymyalgia rheumatica do better? (2020) (1)
AB0014 Nanoparticles as MRI Contrast Agent for Early Diagnosis of RA: Effects of Amino-PVA-Coated SPIONS on CD4+ T Cell Activity (2016) (1)
AB0428 A systematic review on efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis (2017) (1)
Optimization of a Tricalcium Phosphate-Based Bone Model Using Cell-Sheet Technology to Simulate Bone Disorders (2022) (1)
Quantification of morning stiffness to assess disease activity and treatment effects in rheumatoid arthritis. (2021) (1)
[Osteoimmunology-IMMUNOBONE : Regulation of bone by inflammation]. (2018) (1)
Identifying barriers and solutions concerning the recruitment and retention of elderly people in clinical research: Protocol for a Systematic Review v1 (2019) (1)
Balance and prospective falls in patients with rheumatoid arthritis (2022) (1)
[The mechanism of bone loss in rheumatoid arthritis. Description based on a case report]. (2007) (1)
Response to: ‘Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’ by Nokhatha et al (2021) (1)
Identifying barriers and solutions concerning the recruitment and retention of elderly people in clinical research: Protocol for a Systematic Review (2020) (1)
Association Between Participant Retention and the Proportion of Included Elderly People in Rheumatology Trials: Results From a Series of Exploratory Meta‐Regression Analyses (2020) (1)
Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial (2019) (1)
The Anti-Glucocorticoid Receptor Antibody Clone 5E4: Raising Awareness of Unspecific Antibody Binding (2022) (1)
Inhibition of Complex I of the Respiratory Chain, but Not Complex III, Attenuates Degranulation and Cytokine Secretion in Human Skin Mast Cells (2022) (1)
OP0006 Eular evidence-based recommendations on the management of medium to high dose systemic glucocorticoid therapy in rheumatic diseases (2013) (1)
OP0263 FAVORABLE BALANCE OF BENEFIT AND HARM OF LONG-TERM, LOW-DOSE PREDNISOLONE ADDED TO STANDARD TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS AGED 65+: THE PRAGMATIC, MULTICENTER, PLACEBO- CONTROLLED GLORIA TRIAL (2022) (1)
Age-related increase of mitochondrial content in human memory CD4+ T cells contributes to ROS-mediated increased expression of proinflammatory cytokines (2022) (1)
OP0086 Alterations of immune cellular circadian rhythms in rheumatoid arthritis (2013) (1)
[Combination of rare anomalies of the cervical spine and peripheral skeleton]. (1995) (1)
HIF-stabilization prevents delayed fracture healing (2020) (1)
Frequently Used Patient-Reported Outcome (PRO) Measures of General Physical Function Were Highly Correlated With a Multi-Task Performance Outcome (PerfO) Test Battery. (2022) (1)
SP0152 Novel Glucocorticoids and Glucocorticoid Receptor Ligands: Teaching Old Drugs New Tricks (2014) (1)
SAT0090 Analysis of Potential Risk Factors for Delayed Fracture-Healing (2014) (1)
Clinical images: Drummer's finger (1996) (1)
[S2k guidelines (executive summary): management of large-vessel vasculitis]. (2020) (1)
FRI0081 WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS (2019) (1)
[Protracted course of polychondritis as the etiology of progressive nose deformity, subglottic tracheal stenosis and inner ear hearing loss]. (1997) (1)
THU0166 Logistic Regression Method Identifies RA as Risk Factors for Delayed Fracture-Healing – an Update of a Single-Center Retrospective Study (2015) (1)
P235 Glucocorticoid dose is progressively reduced in Patients with rheumatoid arthritis (RA) receiving sarilumab: results from the open label EXTEND study (2020) (1)
SP0097 What is New: Osteoporosis & Bone Diseases (2015) (1)
Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone (2014) (1)
FRI0433 EFFECTS OF DISEASE MODIFYING DRUGS ON BONE MINERAL DENSITY, FRACTURE INCIDENCE, BACK PAIN AND PHYSICAL ACTIVITY IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS (2019) (1)
Anti-TNF antibody therapy does not change serum levels of cortisol binding globulin in patients with rheumatoid arthritis but it increased androstenedione relative to cortisol (2005) (1)
FRI0602 Eular ‘points to consider’ for the conduction of workforce requirement studies in rheumatology (2018) (1)
SP0157 Glucocorticoids: How to Achieve a Good Benefit: Risk Balance Using this Double Edged Sword (2015) (1)
AB0040 PYRUVATE DEHYDROGENASE KINASES AS A POTENTIAL TARGET IN THE TREATMENT OF OSTEOARTHRITIS TO UNLEASH THE METABOLIC FLOW? (2021) (0)
High-Sensitivity Immunofluorescence Staining: A Comparison of the Liposome Procedure and the FASER Technique on mGR Detection (2013) (0)
SAT0055 Simulating the pathogenesis of arthritis in vitro by developing a human-based multicomponent 3d joint model (2018) (0)
OP25. NEW GLUCOCORTICOIDS: SELECTIVE GLUCOCORTICOID RECEPTOR AGONISTS, NO-GLUCOCORTICOIDS AND LONG-CIRCULATING LIPOSOMAL GLUCOCORTICOIDS (2005) (0)
New insights into the fascinating world of glucocorticoids: the dexamethasone-miR-342-Rictor axis in regulatory T cells (2021) (0)
i001 Glucocorticoids: the basic science (2018) (0)
IOF Regionals—1st Middle-East & Africa Osteoporosis Meeting (2011) (0)
AB0060 Modelling delayed bone healing in a mouse-osteotomy model to evaluate therapeutic strategies for affected patients with ra (2017) (0)
AB1009 EXERCISE IS ASSOCIATED WITH HIGHER BONE MINERAL DENSITY IN PATIENTS WITH POLYMYALGIA RHEUMATICA AND VASCULITIDES (2022) (0)
Immune cells in fracture repair (2017) (0)
Response to the Letter to the Editor: Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis (2020) (0)
Low dose glucocorticoid therapy in rheumatic diseases:an obligatory therapy (2010) (0)
Controversies in rheumatology: Maintenance therapy with low-dose glucocorticoids in rheumatoid arthritis. (2022) (0)
Characterization of a disease-inducible interleukin-4 gene therapy in murine articular chondrocytes (2020) (0)
SAT0104 Depression and Anxiety in Patients with An Early Arthritis – A Pilot Study (2016) (0)
Trajectories of Glucocorticoid-Therapy After Initiation in Early (or Methotrexate-Naive) Rheumatoid Arthritis: Protocol for a Systematic Review, Meta-Analysis and Meta-Regression of Observational Cohort Studies v1 (protocols.io.bpyfmptn) (2020) (0)
Inflammatory synovial fluid microenvironment drives primary human chondrocytes to actively take part in inflammatory joint diseases (2011) (0)
A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models (2022) (0)
FRI0019 Human mesenchymal stromal cells reduce TNFα secretion of activated PBMC VIA CTLA-4 (2017) (0)
AB0637 Uv-b skin exposure: a possible mode of treatment for vitamin d deficiency and mood disorders (2013) (0)
AB0767 PATIENTS WITH RHEUMATOID ARTHRITIS HAVE A LOWER BONE DENSITY THAN PATIENTS WITH PSORIATIC ARTHRITIS (2020) (0)
SP0186 Glucocorticoid-Induced Osteoporosis (2016) (0)
AB0144 The Distinct and Overlapping Functions of Hypoxia Inducible Factors in the Adaption Process of Human Microvascular Endothelial Cells to Hypoxia (2015) (0)
AB0023 IMPACT OF METABOLIC CHANGES DURING AGING ON HUMAN EX VIVO NAïVE AND MEMORY CD4+ T CELL FUNCTION (2019) (0)
SAT0042 Disentangling The Role of Hypoxia-Inducible Factor 1 and 2 in The Adaption Process of Human Microvascular Endothelial Cells To Pathophysiological Hypoxia (2016) (0)
POS1410 DEVELOPMENT OF PREDICTION MODELS FOR SENIOR PATIENTS WITH RHEUMATOID ARTHRITIS AND COMORBIDITIES TREATED WITH CHRONIC LOW-DOSE GLUCOCORTICOIDS IN THE GLORIA TRIAL (2022) (0)
Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic, multicenter, placebo-controlled GLORIA trial (2022) (0)
SAT0015 The negative effects of glucocorticoids on bone are primarily mediated by genes involved in osteoblast differentiation and bone remodelling (2013) (0)
[Preliminary consensus statement on glucocorticoid-induced osteoporosis]. (2001) (0)
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica (2023) (0)
FRI0442 Early retirement in patients with rheumatoid arthritis: Effect of morning stiffness (2013) (0)
OP0187 Transgenic disruption of glucocorticoid-signaling in mature osteoblasts and osteocytes attenuates structural bone damage in a long-term murine k/bxn serum-induced arthritis model (2017) (0)
AB1223 RHEUMATOID ARTHRITIS PATIENTS INCLUDED IN GLUCOCORTICOID TRIALS MOSTLY RESEMBLE THOSE SEEN IN OBSERVATIONAL COHORTS: A SYSTEMATIC REVIEW AND META-ANALYSIS (2020) (0)
SAT0564 Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) Expressed in Human Mesenchymal Stromal Cells (2014) (0)
AB0135 Circadian rhythms of immune cells in healthy individuals and patients with rheumatoid arthritis (2018) (0)
SAT0038 Membrane-associated ampd2, a novel regulator in shifting the balance between extracellular atp and adenosine? (2018) (0)
[Pathogenesis and therapy of steroid-induced osteoporosis]. (2001) (0)
OP0105 Accumulation of CD34+ hematopoietic stem cells in the initial inflammatory human fracture hematoma is driven by rantes and eotaxin (2013) (0)
AB0677 Bone mineral density and glucocorticoid treatment in patients with giant cell arteritis and/or polymyalgia rheumatica (2018) (0)
THU0127 Functional activity of membrane-bound glucocorticoid receptors (2013) (0)
Osteoimmunologie – IMMUNOBONE (2018) (0)
FRI0060 Extracellular Macrophage Migration Inhibitory Factor (MIF) Is Essential for Hypoxia-Induced Angiogenesis in A HIF-1-and HIF-2-Independent Manner (2016) (0)
OP0271 Differential regulatory functions of HIF-1α and HIF-2α during angiogenesis of human microvascular endothelial cells (HMECS) (2013) (0)
AB0507 Response of Patient Reported Symptoms of Stiffness and Pain During the Day from Adding Low-Dose Delayed-Release (DR) Prednisone to Stable Dmard Therapy Over 12 Weeks in Patients with Moderate Rheumatoid Arthritis (RA) (2015) (0)
AB0160 HIGH NUMBER OF CONCOMITANT MEDICATIONS AND COMORBIDITIES AT BASELINE IN THE GLUCOCORTICOID LOW-DOSE OUTCOME IN RHEUMATOID ARTHRITIS (GLORIA) STUDY: AN OLDER POPULATION WITH RHEUMATOID ARTHRITIS (2021) (0)
OP0312 METABOLIC REPROGRAMMING IN MEMORY CD4+ T CELLS IS ASSOCIATED WITH REACTIVE OXYGEN INDUCED IMMUNE CELL DYSFUNCTION DURING AGING (2021) (0)
Sociodemographic Characteristics , Lifestyle Factors , and Medical History of Individuals With SSc and Controls (2017) (0)
FRI0040 A Novel Approach to Quantify Morning Stiffness in Patients with Rheumatoid Arthritis (2015) (0)
Arthritis Treated with Nighttime-Release Prednisone Hypothalamus-Pituitary-Adrenal Axis Function in Patients with Rheumatoid (2010) (0)
FRI0369 MIMICKING GLUCOCORTICOID-INDUCED OSTEOPOROSIS USING AN IN VITRO TRABECULAR HUMAN BONE MODEL (2020) (0)
The Circadian Rhythm in Rheumatic Diseases (2009) (0)
Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids (2022) (0)
Bioenergetics of immune functions: Fundamental aspects and clinical importance in chronic inflammatory diseases (2010) (0)
Disentangling the effects of tocilizumab on neutrophil survival and function (2015) (0)
AB1410-HPR Health professionals’ perspective on benefits and risks of low dose glucocorticoids in ra – an initiative under the gloria project (2018) (0)
AB0026 Pathophysiological hypoxia affects both redox state and il-2 signaling of human cd4+ t cells and concomitantly impairs survival and proliferation (2013) (0)
[Hypoxia is a key factor in the inflammatory milieu of rheumatic diseases]. (2012) (0)
OP0086 IMPACT OF GLUCOCORTICOID TAPERING ON MARKERS OF BONE METABOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED LOW DISEASE ACTIVITY OR REMISSION ON TOCILIZUMAB: EXPLORATORY ANALYIS FROM A RANDOMIZED CONTROLLED TRIAL (2019) (0)
Interleukin 6 promotes the growth of breast cancer bone metastasis (2011) (0)
THU0022 The Role of HIF-1 and HIF-2 During Angiogenesis and Metabolic Adaptation of Human Microvascular Endothelial Cells Towards Hypoxia (2013) (0)
[Polyarteritis nodosa - a "classical" case]. (2006) (0)
THU0088 The Bioenergetic Role of HIF-1 and HIF-2 During Angiogenesis of Human Microvascular Endothelial Cells (2013) (0)
Author's response to reviews Title:Acute murine antigen-induced arthritis is not affected by disruption of osteoblastic glucocorticoid signalling Authors: (2013) (0)
THU0088 The Bioenergetic Role of HIF-1 and HIF-2 During Angiogenesis of Human Microvascular Endothelial Cells (2013) (0)
Hypoxia T Cell Proliferation under + Human CD4 Function and Differentially Influences a Suppression of Hypoxia-Inducible Factor-1 Counterregulates Dexamethasone-Mediated Macrophage Migration Inhibitory Factor (2010) (0)
SAT0548 Impact of Glucocorticoids on Mesenchymal Stromal Cell Differentiation - Can Hypoxia Counteract? (2014) (0)
SAT0068 CIRCADIAN RHYTHMS OF IMMUNE SYSTEM IN HEALTHY INDIVIDUALS AND PATIENTS WITH RHEUMATOID ARTHRITIS (2019) (0)
AB0594 Functional ability and quality of life in patients with rheumatoid arthritis treated with low dose modified-release prednisone in daily practice (2013) (0)
AB0636 Alteration of vitamin d after a whole body uv-b exposure in context of a diet (2013) (0)
Optimizing the reporting and conduct of systematic literature reviews and meta-analyses (2023) (0)
University of Southern Denmark Applicability of trials in rheumatoid arthritis and osteoarthritis (2018) (0)
OP0074 TOFACITINIB PROMOTES FUNDAMENTAL PROCESSES OF BONE HEALING (2019) (0)
THU0469 Quantifying the treatment with glucocorticoids as a risk factor for the occurrence of osteoporosis and fractures in patients with ra (2018) (0)
Simulating weightlessness via immobilization impacts immunological parameters (2013) (0)
SP0172 Glucocorticoid-Induced Complications in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis (2016) (0)
Administration of Tramadol or Buprenorphine via the drinking water for post-operative analgesia in a mouse-osteotomy model (2019) (0)
Apoptosis and Caspase Activity in Peripheral Blood Lymphocytes of Patients with Lupus Erythematosus Detected by Flow Cytometry (2005) (0)
POS0665 TRAJECTORIES OF GLUCOCORTICOID-THERAPY IN EARLY RHEUMATOID ARTHRITIS: FIRST RESULTS OF A SCOPING SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL COHORT STUDIES (2021) (0)
[Influence of local anesthetics and narcotics on the energy metabolism of Ehrlich ascites tumor cells]. (1990) (0)
New glucocorticoids on the horizon: repress, don't activate! (2005) (0)
Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody Drug Conjugate, in Adults with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy: a Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase 2a Trial. (2022) (0)
POS0654 IMPACT OF CONCOMITANT GLUCOCORTICOIDS ON THE CLINICAL EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN AD HOC ANALYSIS OF DATA FROM THREE PHASE 3 STUDIES (2021) (0)
[Glucocorticoid therapy in the course of time]. (2005) (0)
Reply (2019) (0)
Glucocorticoids inhibit T cell receptor signaling via Lck and Fyn; a new immunosuppressive mechanism for an old drug (2007) (0)
OP0300 A CROSS-SECTIONAL, MATCHED-PAIR ANALYSIS OF ACPA POSITIVE AND ACPA NEGATIVE RHEUMATOID ARTHRITIS PATIENTS COMPARING THE PREVALENCE OF OSTEOPOROSIS, FRAGILITY FRACTURES AND UNDERLYING RISK FACTORS (2020) (0)
SP0008 Under What Conditions May Long-Term Glucocorticoids Have A Good Benefit-Risk Ratio? (2016) (0)
AB0085 Murine antigen-induced arthritis is not affected by transgenic disruption of osteoblastic glucocorticoid signaling (2013) (0)
The association between the use of oral contraceptives and patient-reported outcomes in an early arthritis cohort: Association of OCs and arthritis outcomes (2015) (0)
AB0092 Controlled Expression of Endogenous Interleukin-4 for Gene Therapeutic Approaches towards Rheumatic Disorders (2014) (0)
Takayasu's arteritis characterised by disturbances of B cell homeostasis responds to B cell depletion with rituximab (2010) (0)
The role of interleukin 6 in a murine model of breast cancer bone metastasis (2010) (0)
Does the cellular composition of the initial fracture hematoma account for scarless bone healing ? (2002) (0)
Immunological characterization of the early human fracture hematoma (2016) (0)
AB0382 Assessing neuropathic pain components in patients with rheumatoid arthritis (2013) (0)
FRI0631 Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction quality appraisal tool (2018) (0)
OP0244 A PRECLINICAL TESTING TOOL: THE IN VITRO 3D FRACTURE GAP MODEL (2020) (0)
CHAPTER 10B – Glucocorticoids (2009) (0)
g THE RELATIONSHIP BETWEEN GAIT & TIBIOFEMORAL BONE STRUCTURE IN KNEE OSTEOARTHRITIS: A PILOT STUDY (2014) (0)
Impact of PVA Coated Nanoparticles On Cellular Viability and Functionality of Immune Cells Obtained From Healthy Donors and Patients With Rheumatoid Arthritis Or Osteoarthritis (2013) (0)
POS1402 COST-EFFECTIVENESS AND COST-UTILITY OF ADD-ON, LOW-DOSE PREDNISOLONE IN RA PATIENTS AGED 65+: THE PRAGMATIC, MULTICENTER, PLACEBO-CONTROLLED GLORIA TRIAL (2022) (0)
Glucocorticoids: Eds N J Goulding, R J Flower. (Pp 216; DM240.) Basel: Birkhäuser, 2001. ISBN 3-7643-6059-3. (Milestones in drug therapy. Series editors M J Parnham, J Bruinvels.) (2002) (0)
and Fyn Rapid immunosuppressive effects of glucocorticoids mediated through Lck (2013) (0)
FRI0015 Modelling the initial phase of fracture healing in vitro – 3d bone-like models of endochondral ossification (2017) (0)
A new perspective is needed for positive selection of germinal center B cells with higher-affinity B cell receptors (2022) (0)
First steps towards the in vitro simulation of an arthritic joint (2018) (0)
SAT-382 Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from the Phase 3/4 SEMIRA Study (2019) (0)
Editor's acknowledgement (2005) (0)
Glucocorticoid-induced cortical bone loss is mediated by osteoblast-controlled activation of bone resorption (2009) (0)
A review on safety : published evidence Low-dose glucocorticoid therapy in rheumatoid (2005) (0)
AB0400 A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS INTO THE SUCCESS RATE OF GLUCOCORTICOID DISCONTINUATION AFTER THEIR USE AS INITIAL BRIDGING THERAPY IN RHEUMATOID ARTHRITIS PATIENTS IN OBSERVATIONAL COHORTS AND CLINICAL TRIALS (2022) (0)
POS1139 GLUCOCORTICOIDS AND BONE DENSITY IN POLYMYALGIA RHEUMATICA, GIANT CELL ARTERITIS, AND OTHER VASCULITIDES – A CROSS-SECTIONAL ANALYSIS OF THE Rh-GIOP COHORT (2022) (0)
[An unusual constellation of findings in polymyositis--differential diagnosis and clinical course]. (1994) (0)
A new perspective is needed for positive selection of germinal center B cells with higher-affinity B cell receptors (2022) (0)
No association between methotrexate and impaired bone mineral density in a cohort of patients with polymyalgia rheumatica, giant cell arteritis, granulomatosis with polyangiitis and other vasculitides—a cross-sectional analysis with dose–response analyses (2023) (0)
AB0031 METABOLIC ADAPTATION OF HUMAN NEUTROPHILS TO GLUCOSE DEPRIVATION IS IMPAIRED WITH INCREASING AGE (2021) (0)
FRI0541 Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 european countries (2013) (0)
THU0119 Impact of Amino-Pva Coated Nanoparticles on Viability and Cytokine Secretion of Human Immune Cells Obtained from Healthy Donors and Patients with Rheumatoid Arthritis (2014) (0)
Metacarpophalangeal joint stiffness is reduced in patients affected by rheumatoid arthritis after glucocorticoid medication (2012) (0)
Placental growth factor-1 (PlGF-1) is related to vascularization, DHEAS to DHEA conversion, and aromatase expression in patients with arthritis—A placental role of PlGF-1 in the synovium (2006) (0)
FRI0264 Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients with Systemic Sclerosis (2016) (0)
Safety and efficacy associated with long-term low dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis. (2023) (0)
prospective trial data rheumatoid arthritis: published evidence and Safety of low dose glucocorticoid treatment in (2008) (0)
Dr. Pembrton's book (1997) (0)
SAT0372 PATIENTS WITH PSORIATIC ARTHRITIS SHOW HIGHER BONE DENSITY COMPARED TO AGE AND GENDER MATCHED PATIENTS WITH ANKYLOSING SPONDYLITIS (2020) (0)
AB0173 Prevention and treatment of corticosteroid-induced osteoporosis in patients with chronic rheumatic diseases (2001) (0)
Expression of placental growth factor–1 (PlGF-1) in synovial tissue from rheumatoid arthritis (RA) patients: Role on inflammation and on DHEAS to DHEA conversion (2007) (0)
[Unilateral sacroiliac joint fusion]. (1998) (0)
Polymyalgia Rheumatica The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in (2017) (0)
FRI0185 Impact of Tocilizumab on Neutrophil Survival and Function (2015) (0)
Reply: Finger exostosis caused by drumming? Comment on the clinical image report by Buttgereit and Burmester (1997) (0)
POS0225 FLUIDIC SHEAR STRESS REDUCES TNFΑ-MEDIATED CARTILAGE DAMAGE IN A 3D MODEL OF DEGENERATIVE JOINT DISEASE (2022) (0)
AB0619 Many peripheral fractures despite normal bone mineral densityin caucasian sle patients (2018) (0)
FRI0004 SURFACE AMP DEAMINASE 2 AS A NOVEL REGULATOR MODIFYING THE EXTRACELLULAR ATP-ADENOSINE BALANCE THAT IS DIFFERENTIALLY EXPRESSED IN PATIENTS WITH RHEUMATOID ARTHRITIS (2020) (0)
OP0014 NO ASSOCIATION BETWEEN THE PROPORTION OF ELDERLY PEOPLE AND TRIAL RETENTION IN RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS TRIALS: A SYSTEMATIC REVIEW WITH META-REGRESSION ANALYSES (2019) (0)
[Specialties in therapy of osteoporosis in inflammatory joint disease]. (2004) (0)
Pyruvate dehydrogenase kinases as a novel target to treat osteoarthritis to unleash the metabolic flow (2021) (0)
OP0270 TAPERING OF LONG-TERM, LOW-DOSE GLUCOCORTICOIDS IN SENIOR RHEUMATOID ARTHRITIS PATIENTS: FOLLOW-UP OF THE PRAGMATIC, MULTICENTRE, PLACEBO-CONTROLLED GLORIA TRIAL (2022) (0)
Chapter 20 Hormonal Modulation of Autoimmune Diseases: Glucocorticoids (2008) (0)
AB0426 Time to Event Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared To, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving DMARDS over 1 Year (2014) (0)
AB0364 Remarkable international variability in reasons for non-participation in the gloria trial (2018) (0)
AB1335-HPR HEALTH PROFESSIONALS’ PERSPECTIVE ON THE BENEFITS AND RISKS OF LOW-DOSE GLUCOCORTICOIDS IN RHEUMATOID ARTHRITIS – AN INTERNATIONAL SURVEY OF 444 HEALTH PROFESSIONALS (2020) (0)
SAT0224 Defining the Conditions Under Which Different Glucocorticoid Doses Have a Good Benefit-Risk Ratio (2015) (0)
PARE0004 PATIENT PERSPECTIVE ON THE EFFICACY AND RISKS OF GLUCOCORTICOIDS IN RHEUMATOID ARTHRITIS – AN INTERNATIONAL SURVEY OF 1344 PATIENTS (2020) (0)
Combining in vito simulation and in silico modelling towards a sophisticated human osteoarthritis model (2019) (0)
THU0637 Patient's and rheumatologist's perspectives on the follow-up interval as a tool for optimized outpatient treatment (2017) (0)
SP0132 How to Assess Glucocorticoid Confounding in the Context of Osteoporosis (2014) (0)
[The DRFZ-a pioneer in research on the interaction between immune and stromal cells during de- and regeneration of the musculoskeletal system]. (2022) (0)
in rheumatic diseases management of systemic glucocorticoid therapy EULAR evidence-based recommendations on the (2008) (0)
Optimal temporal artery biopsy length for diagnosis of giant cell arteritis (2020) (0)
AB0065 Adaptation of human monocytes and macrophages to hypoxia (2013) (0)
Author Correction: Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica (2020) (0)
[Multiple myeloma with antinuclear antibodies. Its course during cytostatic therapy]. (2008) (0)
THU0423 Immobilization Simulating Weightlessness Affects Immunological Parameters (2013) (0)
METACARPOPHALANGEAL JOINT STIFFNESS IS REDUCED AFTER GLUCOCORTICOID THERAPY IN RA PATIENTS (2012) (0)
Pyruvate dehydrogenase kinases as a potential novel target to treat osteoarthritis (2022) (0)
Association between trial retention and the proportion of included elderly individuals: Protocol for a meta-research project v1 (2018) (0)
Membrane glucocorticoid receptors (mGCR) are downregulated by glucocorticoids in SLE-patients and in vitro and are not associated with caveolin-1. (2003) (0)
SAT0450 GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES: A MULTIVARIATE LINEAR REGRESSION ANALYSIS IDENTIFYING PREDICTIVE FACTORS FOR LOW BONE MASS (2020) (0)
Fracture healing disorders as adverse effect of anti-inflammatory medications – How can hif-stabilization be used for prevention in oa or ra patients? (2016) (0)
Clinical images: Aluminum-modified renal osteopathy. (1997) (0)
AB0057 Influence of PVA coated nanoparticles on survival and functionality of human immune cells (2013) (0)
Tocilizumab in Giant Cell Arteritis: Better Understanding the Benefits (2022) (0)
SP0160 2018 eular recommendations for the use of glucocorticoid therapy (2018) (0)
Glucocorticoids (2002) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Frank Buttgereit?

Frank Buttgereit is affiliated with the following schools:

Frank Buttgereit's Academic­Influence.com Rankings

Frank Buttgereit's Degrees

Similar Degrees You Can Earn

Why Is Frank Buttgereit Influential?

Frank Buttgereit's Published Works

Published Works

What Schools Are Affiliated With Frank Buttgereit?

Frank Buttgereit's AcademicInfluence.com Rankings